Owlet (NYSE:OWLT) versus Elutia (NASDAQ:ELUT) Financial Analysis

Owlet (NYSE:OWLT) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Owlet and Elutia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
Elutia	426.93%	-407.37%	-47.08%

Insider & Institutional Ownership

72.6% of Owlet shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 36.2% of Owlet shares are held by company insiders. Comparatively, 17.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Owlet and Elutia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1	1	3	0	2.40
Elutia	1	0	0	0	1.00

Owlet presently has a consensus price target of $15.00, suggesting a potential upside of 197.62%. Given Owlet’s stronger consensus rating and higher possible upside, analysts clearly believe Owlet is more favorable than Elutia.

Valuation & Earnings

This table compares Owlet and Elutia”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70 million	1.39	-$39.68 million	($0.75)	-6.72
Elutia	$12.29 million	2.88	$53.38 million	$0.95	0.84

Elutia has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Owlet has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

About Owlet

Owlet, Inc. provides digital parenting solutions in the United States and internationally. The company's platform focuses on giving real-time data and insights to parents. It offers Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology to track vitals signs, such as pulse rate, oxygen, activity, and sleep patterns; BabySat which is intended for infants with heightened health risk; Owlet Cam, a monitoring device in smartphones that offers video and audio, predictive sleep insights, and cry detections; and accessories, including Owlet Sleeper, as well as Duo and Dream Duo that combines Smart Sock with the Owlet Cam. The company was founded in 2012 and is headquartered in Lehi, Utah.

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.